Basic Information
Dilaforette Holding AB was officially renamed Modus Therapeutics Holding AB on October 26, 2016.Modus Therapeutics is a Swedish biotechnology company developing sevuparin for diseases with unmet medical needs. The company's recent focus is on developing sevuparin for patients with sepsis/septic shock, a severe and often fatal condition.
Modus Therapeutics Holding AB
Stockholm,Stockholm,Sweden
unclear
January 01, 2011
--
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios